polatuzumab vedotin,gemcitabine,mosunetuzumab,oxaliplatin,vedolizumab,rituximab,tocilizumab
takeda,roche,jw pharma
['pola', 'polatuzumab', 'lymphoma', 'lymsm', ' vedo', 'hodgkin', 'mosunetuzumab', 'sunmo']
congress|#asco23 presents the global sunmo trial currently enrolling patients to investigate safety and efficacy of mosunetuzumab+polatuzumab vedotin vs standard of care regimen in patients with r/r b-cell non-hodgkin lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm